Is Pegasys Approved for Chronic Hepatitis B Monotherapy?
Yes, Pegasys (peginterferon alfa-2a) is FDA-approved for chronic hepatitis B monotherapy in adults with HBeAg-positive or HBeAg-negative compensated liver disease.[1] It is given as a single weekly subcutaneous injection for 48 weeks, without requiring combination with nucleoside/nucleotide analogs like lamivudine or tenofovir for initial treatment.[1][2]
How Does Pegasys Work as Monotherapy for HBV?
Pegasys, a pegylated interferon, stimulates the immune response to clear hepatitis B virus (HBV) and induces seroconversion (loss of HBeAg with anti-HBe appearance). In HBeAg-positive patients, it achieves HBeAg seroconversion in about 32% at 48 weeks, compared to 19% with standard interferon.[1] For HBeAg-negative disease, it provides HBV DNA suppression below 100,000 copies/mL in 44% of patients.[1] Unlike oral antivirals, it offers potential for durable off-treatment responses but has more side effects like flu-like symptoms and cytopenias.[2]
When Is Combination Therapy Preferred Over Pegasys Alone?
Guidelines from AASLD recommend Pegasys monotherapy for eligible adults who can tolerate interferon, especially those seeking finite treatment without long-term oral drugs.[3] Combination with antivirals like lamivudine was studied but did not significantly improve outcomes over monotherapy in pivotal trials.[1] However, combinations are used in special cases like lamivudine-resistant HBV or decompensated liver disease, where interferon is contraindicated.[3]
What Are Common Side Effects and Who Should Avoid It?
Patients on Pegasys monotherapy report fatigue (66%), headache (43%), and neutropenia (25%), leading to 10-15% discontinuation rates.[1] It is avoided in decompensated cirrhosis, autoimmune diseases, severe psychiatric issues, or pregnancy.[2][3] Monitoring includes weekly blood counts and thyroid function.
Current Status and Alternatives
Pegasys remains available, though oral nucleoside analogs (entecavir, tenofovir) dominate first-line therapy due to better tolerability and near-100% viral suppression.[3] Interferon is positioned for younger patients or those planning pregnancy after treatment. No pediatric monotherapy approval exists; it's limited to adults.[1]
[1]: FDA Label for Pegasys
[2]: Hepatitis B Foundation on Interferon Therapy
[3]: AASLD Hepatitis B Guidance (2018)